MicroRNA-613 (miR-613)

MicroRNA-613 (miR-613) is a small non-coding RNA (microRNA) molecule that functions as a post-transcriptional regulator of gene expression by binding to complementary sequences in the 3′ untranslated region (3′-UTR) of target mRNAs, leading to mRNA degradation or translational repression[1][2][3][4][5]. MiR-613 is recognized as a tumor suppressor in multiple cancers, including papillary thyroid cancer, lung cancer, colon cancer, and nasopharyngeal carcinoma, where it is typically downregulated; its restoration inhibits cell proliferation, migration, invasion, angiogenesis, and tumor growth both in vitro and in vivo[1][3][4][5][7]. Key experimentally validated gene targets of miR-613 include Sphingosine kinase 2 (SphK2), liver X receptor alpha (LXRα), Fibronectin 1 (FN1), and the neurokinin-1 receptor, implicating miR-613 in diverse processes such as lipid metabolism, carcinogenesis, and tumor microenvironment modulation[1][2][5][7]. The therapeutic modulation of miR-613 is an area of active investigation as a potential strategy for cancer treatment, but no direct drugs have yet been approved. MiR-613's utility as a biomarker and therapeutic target is under scrutiny due to challenges including specificity, delivery, and safety profile of RNA-based therapeutics[1][5].

Other names

hsa-miR-613MIR613MIRN613hsa-mir-613

Downregulation or silencing of oncogenic target genes (e.g., Sphingosine kinase 2 (SphK2), Fibronectin 1 (FN1), Neurokinin-1 receptor, Liver X receptor alpha (LXRα)); Modulation of signaling pathways including AKT signaling